Top

Current Oncology Reports

Published in:

Open Access 24-10-2023 | Mycosis Fungoides

What Is New in Cutaneous T Cell Lymphoma?

Authors: Sarah Morgenroth, Andrea Roggo, Laura Pawlik, Reinhard Dummer, Egle Ramelyte

Published in: Current Oncology Reports | Issue 11/2023

Abstract

Purpose of Review

This review focuses on updates in prognosis, pathogenesis, and treatment of cutaneous T cell lymphoma (CTCL).

Recent Findings

Cohort studies indicate imaging may be necessary in early-stage CTCL. Risk factors for progression of CTCL have been identified. Interactions between malignant cells and the tumor microenvironment (TME) and the skin microbiome advance the understanding of pathogenesis and tumor cell dissemination. Studies support a hypothesis of circulating malignant tumor cells. MicroRNA (miR) influence tumor progression and prognosis; the IL22-STAT3-CCL20 cascade may be a novel target. IL-4, IL-5, and IL-31 cytokines are relevant for pruritus and could be targets for therapeutic interventions. Systemic therapies, such as JAK inhibitors, targeted antibodies, and checkpoint inhibitors, show promise in advanced stages. Allogenic hematopoietic stem cell transplantation provides a potential curative option for patients.

Summary

Further investigations of prognosis and translational research are necessary to improve stratification of patients for treatment.

Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–14.PubMedCentralCrossRef

Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, Geskin LJ, Quaglino P, Ramelyte E. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021. https://doi.org/10.1038/S41572-021-00296-9.

Dobos G, de Masson A, Ram-Wolff C, et al. Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br J Dermatol. 2021;184:1059–67.PubMedCrossRef

Weed J, Girardi M. The difficult—and often delayed—diagnosis of CTCL. Sci Transl Med. 2015. https://doi.org/10.1126/SCITRANSLMED.AAD2518.

Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181:350–7.PubMedCrossRef

Mehta-Shah N, Horwitz SM, Ansell S, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2020;18:522–36.PubMedCrossRef

Maredia H, Cozzio A, Dummer R, Ramelyte E, Kim EJ, Rozati S. Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome. JAAD Case Rep. 2021;15:92–6.PubMedPubMedCentralCrossRef

Scarisbrick JJ. The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas. Presse Med. 2022. https://doi.org/10.1016/J.LPM.2022.104123.

Hodak E, Sherman S, Papadavid E, et al. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol. 2021;184:524–31.PubMedCrossRef

10.

Scarisbrick J, Kim Y. Prognostic factors in mycosis fungoides and Sezary syndrome: results from the PROCLIPI study. Eur J Cancer. 2022;173:S18.CrossRef

11.

Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–22.PubMedCrossRef

12.

Scarisbrick JJ, Hodak E, Bagot M, et al. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018;93:47–56.PubMedCrossRef

13.

Vermeer MH, Moins-Teisserenc H, Bagot M, Quaglino P, Whittaker S. Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach. Br J Dermatol. 2022;187:21–8.PubMedCrossRef

14.

Kalina T, Flores-Montero J, Van Der Velden VHJ, et al (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012 26:9 26:1986–2010.

15.

Najidh S, Tensen CP, van der Sluijs-Gelling AJ, et al. Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome. Blood. 2021;138:2539–54.PubMedCrossRef

16.

Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798–812.PubMedPubMedCentralCrossRef

17.

Rodney IJ, Kindred C, Angra K, Qutub ON, Villanueva AR, Halder RM. Hypopigmented mycosis fungoides: a retrospective clinicohistopathologic study. J Eur Acad Dermatol Venereol. 2017;31:808–14.PubMedCrossRef

18.

Furlan FC, Sanches JA. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. An Bras Dermatol. 2013;88:954–60.PubMedPubMedCentralCrossRef

19.

Villarreal AM, Gantchev J, Lagacé F, Barolet A, Sasseville D, Ødum N, Charli-Joseph YV, Salazar AH, Litvinov IV. Hypopigmented Mycosis Fungoides: Loss of Pigmentation Reflects Antitumor Immune Response in Young Patients. Cancers (Basel). 2020;12:1–21.

20.

Cao S, Kruglov O, Akilov OE. CD8+ T lymphocytes in hypopigmented mycosis fungoides: malignant cells or reactive clone? Journal of Investigative Dermatology. 2023;143:521–524.e3.PubMedCrossRef

21.

van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002. https://doi.org/10.1001/ARCHDERM.138.2.191.

22.

Van Santen S, Roach REJ, Van Doorn R, et al. Clinical staging and prognostic factors in Folliculotropic Mycosis Fungoides. JAMA Dermatol. 2016;152:992–1000.PubMedCrossRef

23.

Hodak E, Amitay-Laish I, Atzmony L, Prag-Naveh H, Yanichkin N, Barzilai A, Kershenovich R, Feinmesser M. New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. J Am Acad Dermatol. 2016;75:347–55.PubMedCrossRef

24.

Mitteldorf C, Stadler R, Sander CA, Kempf W. Folliculotropic mycosis fungoides. JDDG. Journal der Deutschen Dermatologischen Gesellschaft. 2018;16:543–57.PubMedCrossRef

25.

Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.PubMedCrossRef

26.

Krejsgaard T, Lindahl LM, Mongan NP, Wasik MA, Litvinov I V., Iversen L, Langhoff E, Woetmann A, Odum N (2016) Malignant inflammation in cutaneous T-cell lymphoma—a hostile takeover. Seminars in Immunopathology 2017 39:3 39:269–282.

27.

Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19:3755–63.PubMedPubMedCentralCrossRef

28.

Durgin JS, Weiner DM, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Part I, pathways and targets for immune restoration and tumor eradication. J Am Acad Dermatol. 2021;84:587.PubMedCrossRef

29.

Querfeld C, Leung S, Myskowski PL, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018;6:900–9.PubMedPubMedCentralCrossRef

30.

Gluud M, Pallesen EMH, Buus TB, et al. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma. Blood. 2023;141:180–93.PubMedCrossRef

31.

Kalliara E, Belfrage E, Gullberg U, Drott K, Ek S (2023) Spatially guided and single cell tools to map the microenvironment in cutaneous T-cell lymphoma. Cancers 2023, Vol 15, Page 2362 15:2362.

32.

Blümel E, Willerslev-Olsen A, Gluud M, et al. Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma. Oncoimmunology. 2019. https://doi.org/10.1080/2162402X.2019.1641387/SUPPL_FILE/KONI_A_1641387_SM3398.ZIP.

33.

Tegla CA, Herrera AM, Seffens AM, et al. Skin associated staphylococcus aureus contributes to disease progression in CTCL. Blood. 2019;134:659.CrossRef

34.

Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134:1072–83.PubMedPubMedCentralCrossRef

35.

Emge DA, Bassett RL, Duvic M, Huen AO. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. Arch Dermatol Res. 2020;312:283–8.PubMedCrossRef

36.

Dehner CA, Ruff WE, Greiling T, Pereira MS, Redanz S, McNiff J, Girardi M, Kriegel MA. Malignant T cell activation by a bacillus species isolated from cutaneous t-cell lymphoma lesions. JID Innov. 2022;2:100084.PubMedCrossRef

37.

Stowman AM, Hsia LL, Kanner WA, Mahadevan MS, Bullock GC, Patterson JW. Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature. Int J Dermatol. 2016;55:e62–71.PubMedCrossRef

38.

Hamrouni A, Fogh H, Zak Z, Odum N, Gniadecki R. Clonotypic diversity of the T-cell receptor corroborates the immature precursor origin of cutaneous T-cell lymphoma. Clin Cancer Res. 2019;25:3104–14.PubMedCrossRef

39.

Iyer A, Hennessey D, O’Keefe S, Patterson J, Wang W, Wong GKS, Gniadecki R. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma. Blood. 2019;134:1517–27.PubMedCrossRef

40.

Klicznik MM, Morawski PA, Höllbacher B, et al. Human CD4+CD103+ cutaneous resident memory T cells are found in the circulation of healthy individuals. Sci Immunol. 2019;4:8995.CrossRef

41.

Iyer A, Hennessey D, O’Keefe S, Patterson J, Wang W, Wong GKS, Gniadecki R. Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma. Blood Adv. 2020;4:2489–500.PubMedPubMedCentralCrossRef

42.

Herrera A, Cheng A, Mimitou EP, et al. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures. Blood. 2021;138:1456–64.PubMedPubMedCentralCrossRef

43.

Liu X, Jin S, Hu S, et al. Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma. Nature Communications. 2022;13:1–18.

44.

Peiffer L, Gambichler T, Buus TB, et al. Phenotypic plasticity of malignant T cells in blood and skin of a Sézary syndrome patient revealed by single cell transcriptomics. Front Oncol. 2023. https://doi.org/10.3389/FONC.2023.1090592.

45.

Syeda ZA, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory Mechanism of MicroRNA Expression in Cancer. Int J Mol Sci. 2020. https://doi.org/10.3390/IJMS21051723.

46.

Gluud M, Willerslev-Olsen A, Gjerdrum LMR, et al. MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. Cancers (Basel). 2020. https://doi.org/10.3390/CANCERS12051229.

47.

Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.PubMedPubMedCentralCrossRef

48.

Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.PubMedCrossRef

49.

Gallardo F, Sandoval J, Díaz-Lagares A, et al. Notch1 pathway activation results from the epigenetic abrogation of notch-related MicroRNAs in mycosis fungoides. J Invest Dermatol. 2015;135:3144–52.PubMedCrossRef

50.

Sibbesen NA, Kopp KL, Litvinov IV, et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget. 2015;6:20555.PubMedPubMedCentralCrossRef

51.

Wen P, Xie Y, Wang L. The role of microRNA in pathogenesis, diagnosis, different variants, treatment and prognosis of mycosis fungoides. Front Oncol. 2021;11:752817.PubMedPubMedCentralCrossRef

52.

Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 2003;983:84–100.PubMedCrossRef

53.

Abe F, Kitadate A, Ikeda S, et al. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Oncotarget. 2017;8:7572.PubMedCrossRef

54.

Matsuda Y, Ikeda S, Abe F, Takahashi Y, Kitadate A, Takahashi N, Wakui H, Tagawa H. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma. Cancer Sci. 2022;113:1208–19.PubMedPubMedCentralCrossRef

55.

Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67:760–8.PubMedPubMedCentralCrossRef

56.

Winkelmann RK, Caro WA. Current problems in mycosis fungoides and Sézary syndrome. Annu Rev Med. 1977;28:251–69.PubMedCrossRef

57.

Jonak C, Porkert S, Oerlemans S, Papadavid E, Molloy K, Lehner-Baumgartner E, Cozzio A, Efficace F, Scarisbrick J. Health-related quality of life in cutaneous lymphomas: past, present and future. Acta Derm Venereol. 2019;99:640–6.PubMedCrossRef

58.

Wright A, Wijeratne A, Hung T, Gao W, Whittaker S, Morris S, Scarisbrick J, Beynon T. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manage. 2013;45:114–9.PubMedCrossRef

59.

Satoh T, Yokozeki H, Murota H, et al. 2020 guidelines for the diagnosis and treatment of cutaneous pruritus. J Dermatol. 2021;48:e399–413.PubMed

60.

Lewis DJ, Huang S, Duvic M. Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2018;32:1652–6.PubMedCrossRef

61.

Saulite I, Hoetzenecker W, Weidinger S, Cozzio A, Guenova E, Wehkamp U. Sézary syndrome and atopic dermatitis: comparison of immunological aspects and targets. Biomed Res Int. 2016. https://doi.org/10.1155/2016/9717530.

62.

Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21–40.PubMedCrossRef

63.

Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2020;8:83–5.PubMedPubMedCentralCrossRef

64.

Martinelli L, Russomano T, Dos Santos M, Falcao F, Bauer M, MacHado A, Sundaresan A. Effect of microgravity on immune cell viability and proliferation: simulation using 3-D clinostat. IEEE Eng Med Biol Mag. 2009;28:85–90.PubMedCrossRef

65.

Dippel E, Assaf C, Becker JC, et al. S2k-leitlinie – kutane lymphome (ICD10 C82–C86): update 2021. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2022;20:537–55.PubMedPubMedCentral

66.

Ramelyte E, Dummer R, Guenova E. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. 2019;28:799–809. https://doi.org/10.1080/13543784.2019.1654995.CrossRef

67.

Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M (2018) Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv30–iv40.

68.

Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. experience in 79 patients. Arch Dermatol. 1998. https://doi.org/10.1001/ARCHDERM.134.8.949.

69.

Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:325–32.PubMedCrossRef

70.

Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25–32.PubMedPubMedCentralCrossRef

71.

Shipman A, Scarisbrick J. New treatment options for mycosis fungoides. Indian J Dermatol. 2016;61:119.PubMedPubMedCentralCrossRef

72.

Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1998;40:109–15.PubMedCrossRef

73.

Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M. Efficacy and safety of bexarotene combined with psoralen–ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB–IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). Br J Dermatol. 2012;167:678–87.PubMedCrossRef

74.

Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen–UV-a phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:335.PubMedPubMedCentralCrossRef

75.

Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72:286–92.PubMedCrossRef

76.

Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Group for the WBS. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:581–93.PubMed

77.

Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol. 2001;19:2456–71.PubMedCrossRef

78.

Ross C, Tingsgaard P, Jørgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993;51:63–72.PubMedCrossRef

79.

Cheeley J, Sahn RE, Delong LK, Parker SR. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;68:247–54.PubMedCrossRef

80.

Olek-Hrab K, Maj J, Chmielowska E, et al. Methotrexate in the treatment of mycosis fungoides - a multicenter observational study in 79 patients. Eur Rev Med Pharmacol Sci. 2018;22:3586–94.PubMed

81.

Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–91.PubMedCrossRef

82.

Olsen EA, Kim YH, Kuzel TM, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma. J Clin Oncol. 2007;25:3109–15.PubMedCrossRef

83.

Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192–204.PubMedCrossRef

84.

Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30:4091–7.PubMedCrossRef

85.

Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol. 2008;144:727–33.PubMedCrossRef

86.

Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759–65.PubMedPubMedCentralCrossRef

87.

Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5:5098–106.PubMedPubMedCentralCrossRef

88.

Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Cancer. 2005;104:2437–41.PubMedCrossRef

89.

Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: A multicenter phase II study. J Clin Oncol. 2020;38:20–8.PubMedCrossRef

90.

Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168:811–9.PubMedCrossRef

91.

Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Österborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood. 2003;101:4267–72.PubMedCrossRef

92.

Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28:1–37.CrossRef

93.

de Masson A, Beylot-Barry M, Ram-Wolff C, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023;401:1941–50.PubMedCrossRef

94.

Lindberg MR, DiLorenzo A, JA DS. Cutaneous T-cell lymphoma treatment: case series of combination therapy with intralesional injections of 5-fluorouracil and topical imiquimod. Cutis. 2023. https://doi.org/10.12788/CUTIS.0697.

95.

Stadler R, Otte HG, Luger T, Henz BM, Kühl P, Zwingers T, Sterry W. Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a Plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92:3578–81.PubMed

96.

Rook AH, Gelfand JC, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126:1452–61.PubMedPubMedCentralCrossRef

97.

Kim EJ, Mangold AR, Desimone JA, et al. Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): The FLASH phase 3 randomized clinical trial. JAMA Dermatol. 2022;158:1031–9.PubMedPubMedCentralCrossRef

98.

Querfeld C, Thompson JA, Taylor MH, et al. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Lancet Haematol. 2021;8:e808–17.PubMedCrossRef

99.

Ansell SM, Maris MB, Lesokhin AM, et al. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clin Cancer Res. 2021;27:2190–9.PubMedCrossRef

100.

Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20:1160–70.PubMedCrossRef

101.

Liu WT, Wang HT, Yeh YH, Wong TW. An update on recent advances of photodynamic therapy for primary cutaneous lymphomas. Pharmaceutics. 2023;(15):1328.

102.

Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, Handl-Zeller L, Trautinger F, Knobler R. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47:364–70.PubMedCrossRef

103.

O’Malley JT, de Masson A, Lowry EL, et al. Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides. Clin Cancer Res. 2020;26:408–18.PubMedCrossRef

104.

Oymanns M, Daum-Marzian M, Bellm A, Elsayad K, Eich HT, Assaf C. Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma. Br J Dermatol. 2023;188:145–6.PubMedCrossRef

105.

Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. https://www.researchgate.net/publication/340352365_Low-Dose_Intralesional_Recombinant_Interferon-a2b_in_the_Treatment_of_Mycosis_Fungoides. Accessed 9 Jul 2023.

106.

Pérez C, González-Rincón J, Onaindia A, et al. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica. 2015;100:e450.PubMedPubMedCentralCrossRef

107.

Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138:2828–37.PubMedPubMedCentralCrossRef

108.

Pileri A, Clarizio G, Zengarini C, Casadei B, Sabattini E, Agostinelli C, Zinzani PL. Mogamulizumab-associated rashes, their presentation and prognostic significance: a single-centre retrospective case series analysis. J Eur Acad Dermatol Venereol. 2023;37:e615–7.PubMedCrossRef

109.

Reneau JC, Wilcox RA. Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. Semin Hematol. 2021;58:103–13.CrossRef

110.

Gao Y, Hu S, Li R, et al. Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment. JCI Insight. 2023. https://doi.org/10.1172/JCI.INSIGHT.164793.

111.

Su T, Duran GE, Kwang AC, Ramchurren N, Fling SP, Kim YH, Khodadoust MS. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome. Oncoimmunology. 2022. https://doi.org/10.1080/2162402X.2022.2115197/SUPPL_FILE/KONI_A_2115197_SM1867.ZIP.

112.

Phillips D, Matusiak M, Gutierrez BR, et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat Commun. 2021;12:1–18.CrossRef

113.

Domingo-Domenech E, Duarte RF, Boumedil A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021;56(6):1391–401.PubMedCrossRef

Title: What Is New in Cutaneous T Cell Lymphoma?
Authors: Sarah Morgenroth
Andrea Roggo
Laura Pawlik
Reinhard Dummer
Egle Ramelyte
Publication date: 24-10-2023
Publisher: Springer US
Keywords: Mycosis Fungoides
Sézary Syndrome
Lymphoma
Published in: Current Oncology Reports / Issue 11/2023
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01464-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 11/2023

Advances in Treatment of Waldenström Macroglobulinemia

Immune-Related Adverse Events in Patients with Lung Cancer

Chemotherapy-induced peripheral neuropathy

Advances in the management of recurrent cervical cancer

Exercise as Medicine in Cardio-Oncology: Reducing Health Disparities in Hispanic and Latina Breast Cancer Survivors

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer